Author details

Full Name

Cornelis M van Tilburg

Affiliation

ORCID

Career Start Year

2003

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37500667	MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.	Nat Commun	2023
35882450	The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.	Neuro Oncol	2023
35977048	BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma.	Neuro Oncol	2023
37783879	Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.	J Neurooncol	2023
36959034	Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [EurÂ JÂ Cancer 180 (2023) 71-84].	Eur J Cancer	2023
37075810	LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.	Neuro Oncol	2023
37441736	Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies.	Clin Pharmacol Ther	2023
37379234	Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.	Neuro Oncol	2023
37183219	Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.	J Neurooncol	2023
36542877	Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.	Eur J Cancer	2023
37364231	Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.	JCO Precis Oncol	2023
34850167	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.	Neuro Oncol	2022
36182817	Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.	Eur J Cancer	2022
36575299	Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM.	NPJ Precis Oncol	2022
34994601	<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.	JCO Precis Oncol	2021
34050933	A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol Development.	Clin Pharmacol Ther	2021
33865615	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.	Curr Probl Cancer	2021
32822486	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.	Neuro Oncol	2021
33336421	Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data.	Neuropathol Appl Neurobiol	2021
34545083	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B.	Nat Commun	2021
34373263	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.	Cancer Discov	2021
33158040	Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.	Cancers (Basel)	2020
32105622	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.	Lancet Oncol	2020
31986450	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.	Eur J Cancer	2020
32451331	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma Cells.	Mol Cancer Ther	2020
32923898	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.	JCO Precis Oncol	2020
33026636	Response to trametinib treatment in progressive pediatric low-grade glioma patients.	J Neurooncol	2020
32503469	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.	BMC Cancer	2020
31053163	Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2â¿¿years of age - a multicenter retrospective study.	Orphanet J Rare Dis	2019
31823832	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.	Clin Epigenetics	2019
30530705	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma.	Clin Cancer Res	2019
31022591	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.	Eur J Cancer	2019
31108561	SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma.	Klin Padiatr	2019
29230924	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.	Pediatr Blood Cancer	2018
29996150	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making - A Selected Case Series.	Klin Padiatr	2018
29489754	The landscape of genomic alterations across childhood cancers.	Nature	2018
26445087	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.	Brain Pathol	2016
27479119	Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.	Eur J Cancer	2016
21793184	Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases.	Pediatric Blood and Cancer	2012
21051085	Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition.	Leukemia Research	2011
21114483	Immune reconstitution in children following chemotherapy for haematological malignancies: a long-term follow-up.	British Journal of Haematology	2011
21223250	Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity*.	British Journal of Haematology	2011
20006554	Lymphocyte characteristics in children with common variable immunodeficiency.	Clinical Immunology	2010
19586803	Refined characterization and reference values of the pediatric T- and B-cell compartments.	Clinical Immunology	2009
16888619	Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review.	Leukemia	2006
16456212	Health Care Failure Mode and Effect Analysis: a useful proactive risk analysis in a pediatric oncology ward.		2006
14629962	Short-term glucocorticoid treatment of piglets causes changes in growth plate morphology and angiogenesis.	Osteoarthritis and Cartilage	2003